Qulipta – Fast Relief for Migraines, Delivered Differently
Qulipta is changing the way migraines are treated in the U.S. Learn how this fast-acting, oral medication is providing rapid relief and leading the future of migraine care.
Migraines affect over 39 million Americans, causing debilitating pain, nausea, and sensitivity to light and sound. For many, finding fast, effective, and long-lasting migraine relief has been a lifelong challenge—until now.
Qulipta® (atogepant), a once-daily oral CGRP receptor antagonist, is one of the first and only preventive migraine treatments approved for immediate, consistent relief that doesn’t require injections or complex dosing.
How Qulipta Works
Qulipta blocks calcitonin gene-related peptide (CGRP) receptors in the brain, which are involved in migraine attacks. By disrupting this process:
Migraine frequency is reduced
Pain intensity and duration are lessened
Daily life is more manageable without interruption
Unlike traditional triptans, Qulipta doesn't constrict blood vessels, making it a safer option for those with cardiovascular risks.
Why Qulipta Is the Future of Migraine Relief
1.Oral Daily Convenience
No need for injections or nasal sprays—just one tablet a day.
2. Fast Onset of Action
Patients report noticeable relief within the first few doses, making it suitable even for episodic migraine sufferers.
3. Sustained Prevention
Approved for both episodic and chronic migraines, Qulipta is being integrated into long-term migraine management plans.
4. Minimal Side Effects
Most common: constipation, nausea, and fatigue—generally mild and transient.
5. Positive Clinical Results
Phase III trials in the U.S. show significant reduction in monthly migraine days (MMDs) compared to placebo.
Cost & Coverage in the USA
Commercially insured patients may qualify for copay cards through AbbVie’s support program
Covered by Medicare Part D and private insurers, though prior authorization may be required
Average retail cost: ~$950/month without insurance (as of 2025)
What's Next for Qulipta?
AbbVie continues research into combination therapies and expanded indications, including stress-induced and menstrual migraines. The drug’s flexibility and oral delivery position it to compete with injectables like Aimovig and Emgality as the preferred first-line option in the future.